{
"id":"mk19_b_gm_t08",
"number":8,
"bookId":"gm2",
"title":{
"__html":"Recommendations for Prostate Cancer Screening"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"430727",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 8. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_gm_t08"
}
]
},
"Recommendations for Prostate Cancer Screening"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0d8198",
"class":"col hd l",
"children":[
"Expert Group"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c76e38",
"class":"col hd l",
"children":[
"Recommendation"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cd747b",
"class":"cell txt l",
"children":[
"American Cancer Society (2010)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c06e98",
"class":"cell txt l",
"children":[
"Age 40-44 y: Engage men at higher risk (≥2 first-degree relatives with prostate cancer before age 65 y) in shared decision making"
]
},
" ",
{
"type":"p",
"hlId":"24ca8c",
"class":"cell txt l",
"children":[
"Age 45-49 y: Engage men at high risk (African American race or first-degree relative with prostate cancer before age 65 y) in shared decision making"
]
},
" ",
{
"type":"p",
"hlId":"74a145",
"class":"cell txt l",
"children":[
"Age ≥50 y with life expectancy >10 y: Engage in shared decision making"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7bb36f",
"class":"cell txt l",
"children":[
"American College of Physicians (2013)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a7db5c",
"class":"cell txt l",
"children":[
"Age 50-69 y: Inform men about the limited potential benefits and substantial harms of screening for prostate cancer; test only men who request screening after informed discussion"
]
},
" ",
{
"type":"p",
"hlId":"05a57a",
"class":"cell txt l",
"children":[
"Age <50 y, >69 y, or with a life expectancy <10 y: Recommend against screening"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"79679e",
"class":"cell txt l",
"children":[
"American Urological Association (2013; reviewed and confirmed 2015)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e72d95",
"class":"cell txt l",
"children":[
"Men at higher risk (African American race or with positive family history): Individualize screening decisions"
]
},
" ",
{
"type":"p",
"hlId":"37f3dc",
"class":"cell txt l",
"children":[
"Age <40 y: Recommend against screening"
]
},
" ",
{
"type":"p",
"hlId":"1e9a67",
"class":"cell txt l",
"children":[
"Age 40-54 y: Do not recommend routine screening"
]
},
" ",
{
"type":"p",
"hlId":"b8f377",
"class":"cell txt l",
"children":[
"Age 55-69 y: Engage men considering PSA-based screening in shared decision making; proceed on the basis of patient values and preferences. If proceeding with screening, consider PSA testing every 2 y or more"
]
},
" ",
{
"type":"p",
"hlId":"75b732",
"class":"cell txt l",
"children":[
"Age ≥70 y or with life expectancy <10-15 y: Do not recommend routine screening"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2f247a",
"class":"cell txt l",
"children":[
"U.S. Preventive Services Task Force (2018)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4e22f6",
"class":"cell txt l",
"children":[
"Age 55-69 y: Discuss potential benefits and harms of PSA-based screening for prostate cancer and individualize decision making by incorporating the patient's values and preferences"
]
},
" ",
{
"type":"p",
"hlId":"cc49aa",
"class":"cell txt l",
"children":[
"Age ≥70 y: Recommend against PSA-based screening"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"PSA = prostate-specific antigen."
]
]
}